cyrilzakka/clinical-trials huggingface dataset:
Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion

This is a Prospective, open-label, parallel, multi-center, Phase III randomized trial to evaluate the efficacy and safety of video-assisted thoracoscopic segmentectomy versus Lobectomy in treating patients with Lung adenocarcinoma in situ or with microinvasion.

Lobectomy has long been considered the standard procedure for early-stage lung cancer, and minimally invasive techniques have been demonstrated to be associated with superior outcomes compared with lobectomy by thoracotomy. the us of segmentectomy is under investigation for selected patients with small tumors, and the use of minimally invasive strategies is applicable as well.

This nationwide, multicenter, prospective, randomized open phase III study of cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy versus Lobectomy for stage IA non-small cell lung cancer (NSCLC) patients with Lung adenocarcinoma in situ or with microinvasion, is aiming to evaluate the relapse free survival and 5 year overall survival (OS) rate of two types of surgery. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients undergo cVATS lobectomy.
* Arm II: Patients undergo cVATS segmentectomy.

Patients will be followed up every 3 months within the first year, and annually for 5 years postoperatively.

Eligibility Criteria:
Inclusion Criteria:

Preoperative criteria: peripheral non-small cell lung cancer, no larger than 2 cm in maximal diameter, no lymph node metastasis, FEV1%\>50% (FEV1: Forced Expiratory Volume in 1 second);

Preoperative imaging:pure ground-glass or mixed ground-glass nodules (part-solid, solid areas \< 0.5cm);

Follow-up duration last 3 months or more, HRCT (HRCT: high-resolution computed tomography) lesion maximum diameter was measured three times and took the average, meet the criteria of clinical surgical indications;

Intraoperative criteria: histologically confirmed NSCLC, adenocarcinoma in situ or with microinvasion;

No prior ipsilateral thoracotomy;

No prior anti-neoplastic therapy;

EOCG Performance status 0-2;

Sufficient organ functions;

Written informed consent.

Exclusion Criteria:

Active bacterial or fungous infection;

Simultaneous or prior (within the past 5 years) other malignant disease;

Interstitial pneumonitis, pulmonary fibrosis, or severe COPD (COPD: chronic obstructive pulmonary disease);

Abnormal Psychosis;

Uncontrollable diabetes mellitus;

History of severe cardiovascular disease;

Any condition which, in the opinion of the investigator might interfere with the evaluation of the objective.
Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. Certain strains, notably VIM-producing strains, may remain sensitive to carbapenems. CPE VIM strains are rare in France, but represent the main CPE strains in many countries. They are historically the main type of carbapenemases isolated at the Strasbourg University Hospital.

The circulation of multi-antibiotic-resistant bacterial strains is significant at the Strasbourg University Hospital and the investigators wish to report their local experience in the use of carbapenems in infections with enterobacteria producing carbapenemase type VIM.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient (≥18)
* Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022
* Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.

Exclusion Criteria:

* Patient having expressed his opposition to the retrospective reuse of his data for scientific research purposes.
Outcomes of MIST for BPH: A Single-Institution Prospective Study

The investigators wish to perform a prospective study at the Men's Health Clinic in Winnipeg, Manitoba to accomplish two goals: 1) Prospectively describe 1 year outcomes for MIST therapies performed at the clinic 2) perform a head to head comparison of Rezum water vapor therapy vs the iTind device in respect to symptom score improvement, uroflow parameters and side effect profile.

This prospective study is to be conducted at the Men's Health Clinic in Winnipeg, Manitoba. All eligible patients who are to undergo Rezum or iTind procedure for BPH/LUTS between March 2024 and March 2025 are to be included in the study. Patient meeting inclusion criteria and exclusion criteria will be recruited to participate in this study.

Inclusion criteria: patients \> 18 years of age, undergoing Rezum or iTind treatment Exclusion criteria: ASA III or higher, active UTI within past week, age \< 18 years of age, no informed consent Follow-up/data measurements will occur pre-procedure, immediately post procedure, 1 week, 6 weeks, and 3 months following procedure. At time of consultation pre-procedure, baseline symptom scores, uroflow parameters will be obtained. VAS pain score is to be obtained during procedure, immediately post procedure, and at time of catheter or device removal 1 week post procedure. Uroflow parameters and symptoms scores will be again measured at 6 weeks and 3 months.

Eligibility Criteria:
Inclusion Criteria:

* patients \> 18 years of age undergoing Rezum or iTind treatment

Exclusion Criteria:

* ASA 3 or higher, active UTI within past week, age \< 18 years of age, no informed consent
EPT 100: Geranium Oil for the Relief of Neuropathic Pain

The purpose of this study is to determine if Geranium oil will relieve a variety of neuropathic pain and some pain relief will last more than 48 hours.

EPT 100 study is designed to identify the percentage of people who experience neuropathic pain relief from topical geranium oil from Reunion Island, determine which neuropathic pain conditions respond best and define the time course of the pain relief.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or oler
* Neuralgia or neuropathy with daily pain
* At least moderate intensity pain
* Signed informed consent

Exclusion Criteria:

* Pregnant or nursing
* Known allergies to geranium oil or geranium oil fractions
The Relationship Between Fetal Membrane Thickness and Fetal Chromosomal Aneuploidies

This observational study aims to recruit pregnant women between 18 to 24 weeks of gestation to investigate the relationship between amniotic membrane thickness and fetal chromosomal abnormalities. The primary objectives are to establish whether a correlation exists between the measured thickness of the amniotic membrane and the presence of chromosomal abnormalities in the fetus, and to determine a cutoff value for amniotic membrane thickness that could indicate an increased risk of such abnormalities. Additionally, the study seeks to assess whether the inclusion of amniotic membrane thickness as a biomarker can enhance the detection rate of non-invasive prenatal testing (NIPT) and nuchal translucency (NT) for chromosomal abnormalities.


Eligibility Criteria:
Inclusion Criteria:

1. Singleton pregnant women between 18-24 weeks of gestation.
2. Participants with high-risk indications for prenatal fetal chromosomal abnormalities, including:

   * Nuchal translucency (NT) ≥ 3 mm.
   * High-risk results from non-invasive prenatal testing (NIPT) using cell-free fetal DNA from peripheral maternal blood.
   * Ultrasound-detected fetal abnormalities.
   * Other indicators include adverse birth histories, parental chromosomal abnormalities, familial diseases, and a history of thyroid cancer post-surgery.
3. Gestational age and estimated due date were confirmed by the first day of the last menstrual period and adjusted using fetal crown-rump length measured during the first-trimester ultrasound scan.
4. Participants who provided written informed consent for amniocentesis.

   -

Exclusion Criteria:

1. Women with multiple pregnancies or higher-order births.
2. Previous chorionic villus sampling or amniocentesis in the current pregnancy.
3. Gestational age at the time of amniocentesis greater than 25 weeks or less than 18 weeks.
4. Presence of amniotic band syndrome.
5. The presence of uterine anomalies or conditions may impact ultrasound measurements' reliability.
6. Any medical condition or obstetric complication that, in the opinion of the investigators, might pose a risk to the participant or interfere with the study outcomes.
Super Power in BAI

The purpose of this study is to assess the benefit of new super-power bone-anchored hearing aid (BAHA) processors in BAHA users. BAHAs are able to help people with mixed/conductive and single-sided hearing loss when they are unable to use or receive limited benefit from traditional hearing. Until recently, BAHAs were only recommended to people with up to a moderate hearing loss. New super-power BAHA processors may be able to help people who previously were not candidates for BAHAs or received limited benefit from them. The information collected in this study may lead to improved evaluation of and expanded treatment options for people considering BAHA. Different types of hearing tests will be used to compare the devices.

The objective of this study is to assess the benefit of new super-power bone-anchored hearing aid (BAHA) processors in BAHA users. BAHAs are able to help people with mixed/conductive and single-sided hearing loss when they were not receiving benefit from traditional hearing aids or could not use them due to differences in their ears related to surgery or congenital anomalies. Stronger super-power processors may be able to help individuals who previously did not meet candidacy for BAHA. This study will evaluate how much benefit they are getting from their current devices compared to new super-power devices.

The information collected in this study may lead to improved evaluation of patients considering BAHA implantation and expanded treatment options for new and existing BAHA users. Primary outcome measures will include hearing threshold and speech perception measures. All devices are commercially available and FDA approved.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* meet candidacy criteria for a high gain super-power processor with a fitting range up to 65 dB
* native English speaker

Exclusion Criteria:

* do not meet inclusion criteria
Plant-based Dietary Protein and Resistance-training Adaptations

Dietary protein consumption maximizes the anabolic response during resistance training (RT) by triggering muscle protein synthesis and providing the indispensable amino acids for a net positive protein balance. Leucine is considered the key amino acid in this process, suggesting that differences in protein quality may influence RT-induced gains in muscle mass and strength. In general, plant-based protein sources have lower leucine concentrations than animal-based protein sources and human skeletal muscle. In this respect, despite acute evidence on lower anabolic properties of plant- vs. animal-based protein, the effects of an exclusive plant-based dietary protein diet on RT-induced adaptations are currently unknown.


Eligibility Criteria:
Inclusion Criteria:

* Healthy young men
* Vegans ≥ 1 y or omnivorous subjects
* Physically active but no resistance-trained subjects
* Without any chronic injury that impairs resistance training performance
* Protein intake \> 0.8 g/protein/kg body weight

Exclusion Criteria:

* Use of creatine or beta-alanine supplements for the last 3 months
* Use of proteins and/or amino acids supplements for the last 1 month
* Engagement in specific dietary restrictions
* Previous use of anabolic steroids
* Engagement in any training program
New Criteria for Accessory Pathway Localization From Surface ECG

study for discovering new criteria for localization of site of accessory pathway from surface ECG

the study aims for discovering new criteria for percise localization of accessory pathway from surface ECG in referance to final flouroscopic ablation site

Eligibility Criteria:
Inclusion Criteria:

* any patient with manifest accessory pathway .

Exclusion Criteria:

* multiple accessory pathways .previous ablation.
Monitoring of Cerebral Blood Flow in Patients on Extracorporeal Membrane Oxygenation

Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a supportive therapy, indicated in case of severe, possibly reversible pulmonary failure, refractory to conventional therapies. Despite advances, morbidity and mortality remain high. Severe neurological complications can occur during ECMO, but their exact etiology is not well understood. It is hypothesized that fast correction of severe hypercapnia, a common indication for venovenous ECMO, may be detrimental for the brain. The supposed mechanism is that fast correction of hypercapnia may result in massive cerebral vasoconstriction and impaired cerebral blood flow (CBF). In this prospective, observational study the aim is to quantify change in CBF during routine initial correction of severe hypercapnia during VV-ECMO. Furthermore, the investigators will record any other hemodynamic changes during VV-ECMO. The hypothesis is that a larger decline in PaCO2 will result in a larger decline of CBF.


Eligibility Criteria:
Inclusion Criteria: in order to be eligible to participate in this study, a subject must meet all of the following criteria:

* High suspicion of an indication for VV-ECMO;
* Arterial line present to enable blood sampling;
* Older than 18 years.

Exclusion Criteria:

* Subjects will be excluded if the cerebral blood flow cannot be measured using the transcranial Doppler
* VA-ECMO or ECPR;
* No possibility for neuromonitoring measurements due to technical difficulties, e.g. post-craniotomy, unsuitable transcranial window;
* No possibility for neuromonitoring measurements due to circumstantial difficulties, e.g. ECPR;
* Contraindications for ECMO;
* ECMO is initiated in another center.
Confirmatory Study Nepafenac 0.3%

The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.


Eligibility Criteria:
Inclusion Criteria:

* Planned cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens;
* Patients who, in the opinion of the Investigator, would have improvement in best-corrected visual acuity after surgery;
* Able to understand and sign an informed consent;
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Use of topical ocular, inhaled or systemic nonsteroidal anti-inflammatory drugs within 7 days of surgery, with the exception of the allowed low dose of aspirin (up to 100 mg) prior to surgery and through study exit;
* Use of topical ocular, inhaled or systemic steroids within 14 days prior to surgery and through study exit;
* History of chronic or recurrent inflammatory eye disease (eg, iritis, scleritis, uveitis, iridocyclitis, rubeosis iridis) in the operative eye;
* Diabetic retinopathy in the operative eye;
* Known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article;
* Other protocol-defined exclusion criteria may apply.
Analysis of Dietary Intake in Professional Female Football Players

This study evaluates the dietary intake of professional female footballers against nutritional guidelines, analysing differences by age, position, and location (UK vs Spain). Using a cross-sectional design, it will include 20-30 players per club from four clubs, aged 18+, collected via the Snap-N-Send method and analysed with Nutritics software. Variables include energy intake, macronutrients, and micronutrients, with data assessed using MANOVA, t-tests, and Shapiro-Wilk tests. The aim is to determine dietary adequacy and provide insights to improve nutrition education and wellbeing for female athletes.

The aim of this research is to evaluate the dietary intake of female footballers against established nutritional guidelines, while analysing the variables of age, playing position and location to identify if there is a difference in intake across the groups. The study will employ an observational, descriptive, and cross-sectional research design, focusing on female footballers from professional clubs, specifically two clubs in United Kingdom and two clubs in Spain. There is an anticipated sample size of 20 to 30 participants from each club. Inclusion criteria will be female participants who are professional footballers, aged 18 and older and free of disease. Dependent variables from dietary intake will include energy intake (kcal), energy availability (kcal/kg fat free mass/day), protein (g/day), carbohydrates (g/day), fat (%), vitamin D (mg/day), calcium (mg/day) and iron (mg/day). These will be collected using the scientifically valid Snap-N-Send method and analysed with Nutritics dietary analysis software, which has been validated for assessing macronutrients and micronutrients. Independent variables will consist of age groups, playing positions, and country of origin (England or Spain). Dietary intake will be recorded through WhatsApp, with subsequent data entry and storage in Nutritics. Statistical analyses will include MANOVA, used to compare dietary data among groups, one-sample t-test to test against published recommendations and the Shapiro-Wilk test to assess normality in data distribution. This study aims to assess the adequacy of the players' dietary intake in relation to established nutritional recommendations from different backgrounds and characteristics. Furthermore, practitioners can potentially make informed decisions that improve the nutrition education given to female athletes, which contributes to their overall health and wellbeing.

Eligibility Criteria:
Inclusion Criteria:

* Female or assigned female at birth
* Playing football professionally
* At a sub-elite to elite standard
* Above the age of 18
* Healthy and free of disease

Exclusion Criteria:

* Active supplementation with ergogenic aids
* Active pregnancy
* No signing of the consent form
Effects of Eccentric Training on Glycemic Control and Quality of Life in Patients With Type II Diabetes Mellitus

Diabetes is defined by the level of hyperglycemia its a metabolic chronic disorder that furthur lead to life threatning medical conditions however, the prevalence of diabetes is rapidly increasing day by day in both developed and developing countries making it global pandemic and type II is more prevalent. Life dependency is increased due to long term effects of diabetes in specifically older individuals. Physical activity and exercise improves glucose tolerance and also reduces other life threatening diabetic complications, improving the quality of life in diabetic population.

Diabetes is a metabolic chronic disorder and its becoming a global pandemic and its prevalence rises quickly in both developed and developing countries.Diabetes confirmation is done through levels of hyperglycemia. According to American Diabetic Association level of HBA1C is greater than 6.4

% indicate presence of diabetes.Type II is more prevalent and its deteriorting effect on body with increasing age are more pronounced.Insuline resistance and impaired glucose tolerance are seen in type II diabetes mellitus patients.

Studies depict that regular exercise improve glycemic control and improve insuline sensitivity and enhance glucose uptake by muscles.

Strength training enhance quality of life and protect your joints from injury. Previous studies have specified the impact of several types of training on older adults, young healthy adults and diabetic patients but there is limited literature found in terms of solely observing the effect of eccentric training on glycemic control and quality of life in diabetic patient.

Current study was designed to determine the effects of eccentric training on glycemic control and quality of life in type II diabetes Mellitus.

Eligibility Criteria:
Inclusion Criteria:

* Both gender
* Blood pressure should be \<140/90mm of Hg
* Diagnosed Diabetic patient (HBA1C\>6.4%)
* Adults (Age 40 +) from Rawalpindi and Islamabad

Exclusion Criteria:

* Acute infection
* History of recent trauma
* Acute coronary syndrome
* Peripheral vascular diseases
Multicenter Study of Impulse Oscillometry in Chinese

The purpose of this study is to establish the reference values of impulse oscillometry (IOS) in healthy Chinese, and compare the indices of IOS in patients with lung disease, such as chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD), and upper airway Obstruction (UAO).


Eligibility Criteria:
Inclusion Criteria for healthy subjects:

* life-long non-smokers
* no symptoms and history of chronic cardiopulmonary diseases (chronic bronchitis, asthma, lung cancer, pulmonary fibrosis, pulmonary tuberculosis, chronic heart diseases, etc.)
* no abnormal findings on physical examination
* written informed consent was obtained

Inclusion Criteria for COPD:

* Diagnosis of chronic obstructive pulmonary disease (COPD), as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines and post-bronchodilator FEV1/FVC (forced vital capacity) \< 70%.

Inclusion Criteria for asthma:

* Diagnosis of asthma, as classified by national and international asthma guidelines.

Inclusion Criteria for ILD:

* ILD diagnosis confirmed by lung biopsy, X ray or BALF analysis.

Inclusion Criteria for UAO:

* Diagnosis of UAO.

Exclusion Criteria for healthy subjects:

* upper or lower respiratory infection within 4 weeks
* long-term exposure to harmful gas or particles
* using β-blocker for treatment
* pregnant women, epileptic
* other diseases or surgeries potentially affecting lung function
A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)

This long-term study will follow patients with known or suspected of having coronary artery disease (CAD) and have participated in present and future BMS747158 clinical studies. The purpose of this study is to evaluate the long-term predictive value associated with BMS747158 Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI).


Eligibility Criteria:
Inclusion Criteria:

* Have known or suspected CAD
* Have participated in a BMS747158 clinical study
* Have received at least 1 dose of BMS747158
* Provide signed informed consent for this study prior to any follow-up contact
* Be capable of communicating effectively with study personnel

Exclusion Criteria:

* If determined by the Investigator that participation in the study is not in the best interest of the patient or for any sound medical, psychiatric, and/or social reason.
The Effect of Gastric Bypass Surgery on Gut Hormones Related to Bone Remodeling and Intestinal Growth.

The overall purpose is to explore the link between the gut and the bones by investigating meal stimulated changes in the blood level of a number of hormones and markers related to intestinal growth and bone turnover in patients undergoing surgery for obesity (gastric bypass). The hormones will be measured in blood samples taken before and after surgery. The results are compared with changes in body weight and body composition as measured by DEXA scanning.


Eligibility Criteria:
Inclusion Criteria:

* Caucasians fulfilling the criteria for laparoscopic gastric bypass.
* BMI\>40kg/m2.

Exclusion Criteria:

* Pregnancy
* Chronic obstructive pulmonary disease
* Diabetes mellitus
* Chronic inflammatory bowel disease
* Major psychiatric disorder
* Drug abuse